AR-V7 presence detected by immunofluorescent staining was predictive of poor response to AR signaling inhibitors and improved response to taxane therapy, suggesting a potential role for CTC evaluation in directing advanced prostate cancer therapy (40). Here, AR is linked to prostate cancer.